CTMM

AcronymDefinition
CTMMCenter for Translational Molecular Medicine
CTMMCalifornia Test of Mental Maturity
CTMMCity of Tshwane Metropolitan Municipality (Pretoria, Gauteng, South Africa)
CTMMCommonwealth Tourism Ministers' Meeting
CTMMComputed Tomography Metrizamide Myelography
References in periodicals archive ?
The CTMM (Center for Translational Molecular Medicine) is a Netherlands-based public-private partnership.
Despite these limitations, the approach seemed reasonable and simple for approximating ART need (total and initiation) among adults in the CTMM.
Thus, these data cannot be used to calculate the ART need in the CTMM and the trend in ART coverage cannot be monitored over the years of the CTMM study.
An estimate of the number of adults (15-49 years) living in the CTMM was made by multiplying the number of adults in Gauteng (Statistics South Africa mid-year population estimates 2010) (1) by the proportion of the total population of the province living in the CTMM (Community Survey 2007 data).
1) Total need for ART in the CTMM was calculated by multiplication of this figure by the proportion of the total population of South Africa living in the CTMM (Community Survey 2007).
For the estimated need for services for orphaned and vulnerable children (OVC), the estimated number of maternal AIDS orphans (<18 years) in the CTMM was calculated by applying the proportion of the total population of Gauteng living in the CTMM (using data from the Community Survey 2007) to the number of orphans in the province (using data from the ASSA2008 model).
HCT: the number of adults (15-49 years) in the CTMM is estimated to be 1 435 438, which indicates the estimated need for HCT services.
ART: the total ART need of adults (15+ years) in the CTMM is 75 211, with 30 713 in need of ART initiation.
Care for OVC: the estimated number of maternal AIDS orphans (<18 years) in the CTMM was 54 590.
The CTMM program for leukemia will give an enormous stimulus to the development of various innovative technologies for diagnosis and prognosis in leukemia and myeloma that should generate new useful tools for personalized therapeutics.
CTMM is a public-private consortium that comprises a multidisciplinary group of parties - universities, academic medical centers, medical technology enterprises and chemical and pharmaceutical companies.